SCHEMBL16745388

SCHEMBL16745388

Nc1ccc2c(=O)c3c(sc4c(=O)c5cc(N)ccc5c(=O)c43)c(=O)c2c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.41
SMN1; SMN2 Q16637 4/20 0.41
NPC1 O15118 4/20 0.41
MAPT P10636 2/20 0.41
GFER P55789 1/20 0.41
PARP1 P09874 3/20 0.38
ALDH1A1 P00352 4/20 0.36
HPGD P15428 3/20 0.36
KMT2A Q03164 3/20 0.33
AR P10275 2/20 0.33
KDM4E B2RXH2 2/20 0.33
GAA P10253 2/20 0.33
CASP1 P29466 2/20 0.33
CASP7 P55210 2/20 0.33
HSD17B10 Q99714 2/20 0.33
SRC P12931 2/20 0.33
MEN1 O00255 2/20 0.33
ATM Q13315 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
TLR9 Q9NR96 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16745384 1.00 RAB9A (0.41) RAB9ASMN1; SMN2NPC1MAPTGFER
SCHEMBL16745382 1.00 RAB9A (0.41) RAB9ASMN1; SMN2NPC1MAPTGFER
SCHEMBL16745380 0.95 RAB9A (0.44) RAB9ASMN1; SMN2NPC1MAPTGFER
SCHEMBL16745385 0.95 RAB9A (0.44) RAB9ASMN1; SMN2NPC1MAPTGFER
SCHEMBL18193055 0.90 NPC1 (0.35) RAB9ASMN1; SMN2NPC1MAPTGFER
SCHEMBL16745413 0.90 NPC1 (0.35) RAB9ASMN1; SMN2NPC1MAPTGFER
SCHEMBL18193056 0.90 NPC1 (0.35) RAB9ASMN1; SMN2NPC1MAPTGFER
SCHEMBL31206431 0.77 RAB9A (0.48) RAB9ASMN1; SMN2NPC1MAPTGFER
SCHEMBL12478397 0.77 RAB9A (0.48) RAB9ASMN1; SMN2NPC1MAPTGFER
SCHEMBL18193065 0.77 ALDH1A1 (0.38) SMN1; SMN2NPC1MAPTPARP1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9481662-B2 Seriniquinones, melanoma-specific anticancer agents THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2016-11-01 US disclosed
US-9481662-B2 Seriniquinones, melanoma-specific anticancer agents THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2016-11-01 US disclosed
US-20150148314-A1 SERINIQUINONES, MELANOMA-SPECIFIC ANTICANCER AGENTS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-05-28 US disclosed
US-20150148314-A1 SERINIQUINONES, MELANOMA-SPECIFIC ANTICANCER AGENTS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-05-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150148314-A1 SERINIQUINONES, MELANOMA-SPECIFIC ANTICANCER AGENTS SDHA, KLK3, BRDT RAB9A 2471/4885SMN1; SMN2 2167/4885NPC1 3954/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.